uniQure has made progress in advancing its gene therapy candidates, including AMT-130 for Huntington's disease; additional data from phase I/II study expected Q4 of 2023. Interim data from the phase I ...
uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression. The company ...
On November 3, 2025, uniQure announced that the FDA now questions whether Phase I/II data for AMT-130 are sufficient as primary evidence for a Biologics License Application, introducing uncertainty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback